Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Actinogen Medical Limited

Investor presentation - Actinogen Medical Limited

ASX:ACW

Actinogen Medical Limited

Health

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.

Read more

Market Cap

$31.92m

Price at Close

$0.022

4w avg. Volume

1.26m

4w avg. Turnover

$26.49k

Announcements
announcementt+2 movementdate
  • Review of 2020 and outlook

    Progress Report

  • 0.00%

    16 Dec 2020

0.00%

16 Dec 2020
  • Replacement Constitution

    Company Administration

  • -4.55%

    27 Nov 2020

-4.55%

27 Nov 2020
  • Results of Annual General Meeting

    Notice Of Meeting

  • -4.55%

    27 Nov 2020

-4.55%

27 Nov 2020
  • AGM Presentations

    Periodic Reports

  • -4.35%

    26 Nov 2020

-4.35%

26 Nov 2020
  • Appendix 3Y x 4

    Shareholder Details

  • -4.35%

    17 Nov 2020

-4.35%

17 Nov 2020
  • Appendix 2A

    Issued Capital

  • -4.35%

    17 Nov 2020

-4.35%

17 Nov 2020
  • Completion of Entitlement Offer

    Issued Capital · Market sensitive

  • 0.00%

    12 Nov 2020

0.00%

12 Nov 2020
  • Actinogen files new patent applications

    Progress Report · Market sensitive

  • +4.55%

    08 Nov 2020

+4.55%

08 Nov 2020
  • Retail Entitlement Offer-Closing Date Reminder

    Issued Capital

  • 0.00%

    04 Nov 2020

0.00%

04 Nov 2020
  • FDA IND Update

    Progress Report · Market sensitive

  • 0.00%

    03 Nov 2020

0.00%

03 Nov 2020
Market Data

Current Price

$0.022

52WK HIGH

$0.042

52WK LOW

$0.015

1YR RETURN

-43.59%

1YR RETURN VS. SECTOR

-82.28%

90 DAY RETURN

0.00%

ASX RANK

1,358

/2,048

SECTOR RANK

130

/168

SHARES OUTSTANDING

1.45b
ASX:ACW

Actinogen Medical Limited

Health

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.

Read more

Market Cap

$31.92m

Price at Close

$0.022

4w avg. Volume

1.26m

4w avg. Turnover

$26.49k

ASX:ACW is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.